Benayed R, Offin M, Mullaney K, et al. Comprehensive detection of targetable fusions in lung adenocarcinomas by complementary targeted DNAseq and RNAseq assays. Presented at: 2018 American Society of Clinical Oncology Annual Meeting; June 1-5, 2018; Chicago, IL. Abstract 12076.
Church AJ, Calicchio ML, Nardi V, et al. Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy. Mod Pathol. 2018;31:463-473.
Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;15:731-747.
Demetri GD, Paz-Ares L, Farago AF, et al. Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) tumors: pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001. Presented at: 2018 European Society for Medical Oncology Conference; October 19-23, 2018; Munich, Germany. Abstract LBA17.
Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378:731-739.
Drilon A, Li G, Gounder M, et al. What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC). Ann Oncol. 2016;27:920-926.
Drilon A, Nagasubramanian R, Blake JF, et al. A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion-positive solid tumors. Cancer Discov. 2017;7:963-972.
Drilon A, Ou SHI, Cho BC, et al. A phase 1 study of the next-generation ALK/ROS1/TRK inhibitor ropotrectinib (TPX-0005) in patients with advanced ALK/ROS1/NTRK+ cancers (TRIDENT-1). Presented at: 2018 American Society of Clinical Oncology Annual Meeting; June 1-5, 2018; Chicago, IL. Abstract 2513.
Drilon A, Siena S, Ou SI, et al. Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 2017;7:400-409.
Gatalica Z, Xiu J, Swensen J, et al. Molecular characterization of cancers with NTRK gene fusions. Mod Pathol. 2018. doi:10.1038/s41379-018-0118-3. [Epub ahead of print]
Gulley ML, Braziel RM, Halling KC, et al. Clinical laboratory reports in molecular pathology. Arch Pathol Lab Med. 2007;131:852-863.
Hechtman JF, Benayed R, Hyman DM, et al. Pan-Trk immunohistochemistry is an efficient and reliable screen for the detection of NTRK fusions. Am J Surg Pathol. 2017;41:1547-1551.
Hung YP, Fletcher CDM, Hornick JL. Evaluation of pan-TRK immunohistochemistry in infantile fibrosarcoma, lipofibromatosis-like neural tumour and histological mimics. Histopathology. 2018;73:634-644.
Khotskaya YB, Holla VR, Farago AF, et al. Targeting TRK family proteins in cancer. Pharmacol Ther. 2017;173:58-66.
Krings G, Joseph NM, Bean GR, et al. Genomic profiling of breast secretory carcinomas reveals distinct genetics from other breast cancers and similarity to mammary analog secretory carcinomas. Mod Pathol. 2017;30:1086-1099.
Kumar-Sinha C, Kalyana-Sundaram S, Chinnaiyan AM. Landscape of gene fusions in epithelial cancers: seq and ye shall find. Genome Med. 2015;7:129.
Lassen UN, Albert CM, Kummar S, et al. Larotrectinib efficacy and safety in TRK fusion cancer: an expanded clinical dataset showing consistency in an age and tumor agnostic approach. Presented at: 2018 European Society for Medical Oncology Conference; October 19-23, 2018; Munich, Germany. Abstract 409O.
NTRK1. The Human Protein Atlas website. https://www.proteinatlas.org/ENSG00000198400-NTRK1/tissue. Accessed November 1, 2018.
NTRK2. The Human Protein Atlas website. https://www.proteinatlas.org/ENSG00000148053-NTRK2/tissue. Accessed November 1, 2018.
NTRK3. The Human Protein Atlas website. https://www.proteinatlas.org/ENSG00000140538-NTRK3/tissue. Accessed November 1, 2018.
Rubin BP, Chen CJ, Morgan TW, et al. Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma. Am J Pathol. 1998;153:1451-1458.
Skálová A, Vanecek T, Sima R, et al. Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Am J Surg Pathol. 2010;34:599-608.
The UniProt Consortium. Nucleic Acids Research; 2017;45:D158-D169.
UniProt website. https://www.uniprot.org. Accessed November 26, 2018.
Vaishnavi A, Le AT, Doebele RC. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov. 2015;5:25-34.
Wiesner T, He J, Yelensky R, et al. Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. Nat Commun. 2014;5:3116.
Wong V, Pavlick D, Brennan T, et al. Evaluation of a congenital infantile fibrosarcoma by comprehensive genomic profiling reveals an LMNA-NTRK1 gene fusion responsive to crizotinib. J Natl Cancer Inst. 2015;108:djv307.
Zheng Z, Liebers M, Zhelyazkova B, et al. Anchored multiplex PCR for targeted next-generation sequencing. Nat Med. 2014;20:1479-1484.

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Moderator

Eric Q. Konnick, MD

Assistant Professor
Associate Director
Genetics and Solid Tumor Lab
Director
Genetics Preanalytical Services
University of Washington Medical Center
Seattle, Washington

Disclosures

Disclosure: Eric Q. Konnick, MD, has disclosed the following relevant financial relationships:
Served as a speaker or a member of a speakers bureau for: Ventana Medical Systems

Panelists

Dara L. Aisner, MD, PhD

Associate Professor
University of Colorado School of Medicine
Aurora, Colorado

Disclosures

Disclosure: Dara L. Aisner, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; Bayer HealthCare; Bristol-Myers Squibb Company; Genentech, Inc.
Received grants for clinical research from: Genentech, Inc.

Todd M. Bauer, MD

Associate Director, Drug Development
Physician Lead, Personalized Medicine
Sarah Cannon Research Institute
Tennessee Oncology, PLLC
Nashville, Tennessee

Disclosures

Disclosure: Todd M. Bauer, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Guardant Health; Ignyta; Loxo Oncology; Moderna Therapeutics; Pfizer Inc.
Received grants for clinical research from: AbbVie Inc.; Aileron Therapeutics; Amgen Inc.; Astellas Pharma, Inc.; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Calithera Biosciences; Clovis Oncology; Daiichi Sankyo, Inc.; Deciphera; Five Prime Therapeutics; Foundation Medicine; Genentech, Inc.; GlaxoSmithKline; Ignyta; Immunocore; Immunogen; Incyte Corporation; Jacobio; Janssen Pharmaceuticals; Karyopharm Therapeutics; Kolltan Pharmaceuticals; Leap Therapeutics; Lilly USA, LLC; Loxo; MabVax; MedImmune Inc.; Medpacto, Inc.; Merck & Co., Inc.; Merrimack; Millennium; Mirati Therapeutics; Moderna Therapeutics; Novartis Pharmaceuticals Corporation; Onyx; Peleton; Pfizer Inc.; Phosplatin Therapeutics; Principa Biopharma; Roche; Sanofi; Stemline Therapeutics; Top Alliance BioScience; Takeda Pharmaceuticals North America, Inc.
Other: Fees paid to TMB/SCRI

Editors

Elaine Hamarstrom, PhD

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Elaine Hamarstrom, PhD, has disclosed no relevant financial relationships.

Mindy Tanzola, PhD

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Mindy Tanzola, PhD, has disclosed no relevant financial relationships.

AMP Reviewer

Lucia Barker, PhD

Director, Education Programs
Association for Molecular Pathology

Disclosures

Disclosure: Lucia Barker, PhD, has disclosed no relevant financial relationships.

CME Reviewer

Nafeez Zawahir, MD

CME Clinical Director, Medscape, LLC

Disclosures

Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed the following relevant financial relationships:
Boehringer Ingelheim; Ipsen BioPharmaceuticals

CME / ABIM MOC

Emerging Targets for the Diagnosis of Cancer: NTRK Fusion in Solid Tumors

Authors: Eric Q. Konnick, MD; Dara L. Aisner, MD, PhD; Todd M. Bauer, MD
CME / ABIM MOC Released: 12/12/2018
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 12/12/2019, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This activity is intended for pathologists and oncologists.

The goal of this activity is to improve the identification and management of patients with NTRK fusion-positive solid tumors using the most current evidence base.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Clinical trial data supporting treatment selection in patients with NTRK fusion-positive solid tumors
Have greater competence related to
- The most appropriate testing strategy for detection of NTRK fusions to allow accurate characterization of a patient's cancer
- Accurate reporting of biomarker test results to other members of the care team to help guide optimal treatment selection throughout the continuum of a patient's disease

Disclosures

Moderator

Eric Q. Konnick, MD

Assistant Professor
Associate Director
Genetics and Solid Tumor Lab
Director
Genetics Preanalytical Services
University of Washington Medical Center
Seattle, Washington

Disclosures

Disclosure: Eric Q. Konnick, MD, has disclosed the following relevant financial relationships:
Served as a speaker or a member of a speakers bureau for: Ventana Medical Systems

Panelists

Dara L. Aisner, MD, PhD

Associate Professor
University of Colorado School of Medicine
Aurora, Colorado

Disclosures

Disclosure: Dara L. Aisner, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; Bayer HealthCare; Bristol-Myers Squibb Company; Genentech, Inc.
Received grants for clinical research from: Genentech, Inc.

Todd M. Bauer, MD

Associate Director, Drug Development
Physician Lead, Personalized Medicine
Sarah Cannon Research Institute
Tennessee Oncology, PLLC
Nashville, Tennessee

Disclosures

Disclosure: Todd M. Bauer, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Guardant Health; Ignyta; Loxo Oncology; Moderna Therapeutics; Pfizer Inc.
Received grants for clinical research from: AbbVie Inc.; Aileron Therapeutics; Amgen Inc.; Astellas Pharma, Inc.; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Calithera Biosciences; Clovis Oncology; Daiichi Sankyo, Inc.; Deciphera; Five Prime Therapeutics; Foundation Medicine; Genentech, Inc.; GlaxoSmithKline; Ignyta; Immunocore; Immunogen; Incyte Corporation; Jacobio; Janssen Pharmaceuticals; Karyopharm Therapeutics; Kolltan Pharmaceuticals; Leap Therapeutics; Lilly USA, LLC; Loxo; MabVax; MedImmune Inc.; Medpacto, Inc.; Merck & Co., Inc.; Merrimack; Millennium; Mirati Therapeutics; Moderna Therapeutics; Novartis Pharmaceuticals Corporation; Onyx; Peleton; Pfizer Inc.; Phosplatin Therapeutics; Principa Biopharma; Roche; Sanofi; Stemline Therapeutics; Top Alliance BioScience; Takeda Pharmaceuticals North America, Inc.
Other: Fees paid to TMB/SCRI

Editors

Elaine Hamarstrom, PhD

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Elaine Hamarstrom, PhD, has disclosed no relevant financial relationships.

Mindy Tanzola, PhD

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Mindy Tanzola, PhD, has disclosed no relevant financial relationships.

AMP Reviewer

Lucia Barker, PhD

Director, Education Programs
Association for Molecular Pathology

Disclosures

Disclosure: Lucia Barker, PhD, has disclosed no relevant financial relationships.

CME Reviewer

Nafeez Zawahir, MD

CME Clinical Director, Medscape, LLC

Disclosures

Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed the following relevant financial relationships:
Boehringer Ingelheim; Ipsen BioPharmaceuticals

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Oncology

CME / ABIM MOC

Emerging Targets for the Diagnosis of Cancer: NTRK Fusion in Solid Tumors

Authors: Eric Q. Konnick, MD; Dara L. Aisner, MD, PhD; Todd M. Bauer, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC Released: 12/12/2018

Valid for credit through: 12/12/2019, 11:59 PM EST

processing....

Educational Impact Challenge

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Page 1 of 4

CME / ABIM MOC Information Download Slides

Print
Like Tweet

Developed through a partnership between Medscape and Association for Molecular Pathology (AMP).

Disclaimer

The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.

The material presented here does not necessarily reflect the views of Medscape, LLC, or companies that support educational programming on medscape.org. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

References

Faculty and Disclosures

Moderator

Eric Q. Konnick, MD

Panelists

Dara L. Aisner, MD, PhD

Todd M. Bauer, MD

Editors

Elaine Hamarstrom, PhD

Mindy Tanzola, PhD

AMP Reviewer

Lucia Barker, PhD

CME Reviewer

Nafeez Zawahir, MD

Peer Reviewer

CME / ABIM MOC

Emerging Targets for the Diagnosis of Cancer: NTRK Fusion in Solid Tumors

Target Audience and Goal Statement

Disclosures

Moderator

Eric Q. Konnick, MD

Panelists

Dara L. Aisner, MD, PhD

Todd M. Bauer, MD

Editors

Elaine Hamarstrom, PhD

Mindy Tanzola, PhD

AMP Reviewer

Lucia Barker, PhD

CME Reviewer

Nafeez Zawahir, MD

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Emerging Targets for the Diagnosis of Cancer: NTRK Fusion in Solid Tumors

Educational Impact Challenge